Participants were randomly assigned following simple randomization procedures. Eligible subjects were randomly divided into 2 groups: IFNα-2b plus RBV (IFNα-2b/RBV) group (n = 37), patients underwent therapy of recombinant IFNα-2b (300 million units for body weight<60 kg and 500 million units for body weight≥60 kg, on alternate days) (Beijing Kawin Technology Share-holding Co, Ltd. China) plus weight-based RBV (13–15 mg/kg⋅d) (Zhejiang Chengyi pharmaceuticals Co, Ltd. China); PegIFNα-2a plus RBV (PegIFNα-2a/RBV) group (n = 33), patients received PegIFNα-2a (135 μg/week for body weight<60 kg and 180 μg/week for body weight≥60 kg, subcutaneously) (Pegasys, Roche, Basel, Switzerland) plus weight-based RBV (13–15 mg/kg⋅d) (Fig. 1 ). Responses to the treatment were assessed by detecting plasma HCV RNA levels at baseline, 12 and 24 weeks after the treatment. Standard definitions of responses were used to evaluate the therapeutic effect [18] (link). Complete early virological response (cEVR) was defined as undetectable plasma HCV RNA at 12 weeks after treatment. Full details of the trial protocol can be found in the Supplementary Appendix, available with the full text of this article at www.chictr.org/cn/ .
Pegifnα 2a
Manufactured by Roche
Sourced in Switzerland, China, United States
PegIFNα-2a is a type of pegylated interferon alpha-2a, a protein-based medication used in the treatment of certain viral infections. It functions by modifying the immune system to help fight the viral infection.
Automatically generated - may contain errors
Lab products found in correlation
Pegasys, by Roche (2 mentions)
Ribavirin, by Selleck Chemicals (2 mentions)
Bx795, by Selleck Chemicals (2 mentions)
Mrt67307, by Selleck Chemicals (2 mentions)
Fetal bovine serum (fbs), by Thermo Fisher Scientific (2 mentions)
Pegintron, by Merck & Co (2 mentions)
Baraclude, by Bristol-Myers Squibb (1 mentions)
Hek293, by American Type Culture Collection (1 mentions)
Hepg2, by American Type Culture Collection (1 mentions)
A549 cell line, by American Type Culture Collection (1 mentions)
Bl21 de3, by Merck Group (1 mentions)
Pet11a, by Merck Group (1 mentions)
Lipopolysaccharides (lps), by Roche (1 mentions)
Peg ifn α2b, by Merck & Co (1 mentions)
Rebetol, by Merck & Co (1 mentions)
Copegus, by Roche (1 mentions)
18 protocols using pegifnα 2a
1
Randomized Trial of IFNα-2b/RBV vs PegIFNα-2a/RBV in HCV
2
PEG-IFNα-2a Therapy for CHB Patients
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients were treated with 180 μg iH of PEG-IFNα-2a (Pegasys, Roche) once weekly for 48 weeks, and the dosage was adjusted according to any adverse effects identified by their physicians. After initiating the PEG-IFNα-2a treatment, the patients were followed-up at the outpatient clinics every 4 weeks. In addition to conventional biochemistry tests, the quantification of serum HBsAg, anti-HBs, HBeAg, anti-HBe, and HBV DNA was performed at baseline and at week 12 or 24, 48, and 72. Complete response (CR) was defined as a serum HBV DNA level less than 500 IU/mL, normal ALT levels (<40 IU/L), and HBeAg seroconversion (HBeAg loss and anti-HBe-positive) at 48 weeks posttreatment and 24 weeks follow-up. Virological response (VR) was defined as a serum HBV DNA level of less than 500 IU/mL. Biochemical response (BR) was defined as ALT and AST levels returning to normal. The following cases were discontinued during treatment: patients who had difficulty tolerating the side effects and patients who refused to continue antiviral therapy. The following cases were discontinued during 24 weeks follow-up: patients who had an elevation of ALT levels >10 times ULN; patients who refused to continue following up and switch to nucleoside analogues (NAs) therapy.
3
Entecavir vs. Pegylated Interferon for Chronic Hepatitis B
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This study was a 48-wk prospective and retrospective treatment trial comparing the efficacy and safety of 0.5 mg entecavir (ETV, Baraclude, Bristol-Myers Squibb) daily for 48 wk compared to switching to pegylated interferon alpha-2a (PegIFNα-2a, F. Hoffmann-La Roche Ltd, Basel, Switzerland). All patents were followed up for 24 wk (Figure 1 ). Patients assigned to PegIFNα-2a received 180 μg/wk for 48 wk, with the first 12 wk overlapping with 0.5 mg daily ETV. Patients assigned to the ETV group continued with ETV monotherapy. A total of 88 patients who had received ETV treatment for at least 48 wk were recruited from the Second Hospital affiliated with Guangzhou Medical University between January 1, 2013, and December 31, 2015. Patients were randomized to receive PegIFNα-2a 180 μg/wk or continue 0.5 mg daily ETV for 48 wk. Eligible patients were HBsAg-positive, had serum HBV-DNA < 500 IU/mL, serum HBeAg < 100 S/CO, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels < 2 × the upper limit of normal (ULN) of 40 IU/L. Patients with decompensated cirrhosis and HCC were excluded; as were patients co-infected with hepatitis A, C, or D; those who had been pre-treated with other antivirals; and patients with a history or evidence of other chronic liver diseases, including autoimmune hepatitis or alcohol liver disease.
4
Chronic Hepatitis C Treatment Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients with chronic hepatitis C were treated with pegylated IFNα-2a (PegIFNα-2a; 135µg/week for body weight < 60 kg and 180µg/week for body weight ≥ 60 kg, subcutaneously; Pegasys, Roche, Basel, Switzerland) plus weight-based RBV (13–15 mg/kg per day; Zhejiang Chengyi Pharmaceutical Co., Ltd, Zhejiang, China). Treatment continued for 44 weeks after HCV RNA was undetectable. Standard definitions of responses were used. Complete early virological response (cEVR) was defined as undetectable plasma HCV RNA at week 12 during therapy, and sustained virological response (SVR) was defined as undetectable HCV RNA at 24 weeks after planned end of treatment.
5
Cytokine-Stimulated FDC Interactions
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Cultured FDCs were stimulated with IL-4 (30 ng/mL), IL-10 (30 ng/mL), IL-21 (30 ng/mL), lipopolysaccharide (LPS, 1 μg/mL), Peg-IFNα-2a (2 μg/mL, Roche, Shanghai, China), lymphotoxin-α1β2 (10 ng/mL), tumor necrosis factor (TNF)-α (10 ng/mL), CPG (5 μg/mL), or PMA (50 ng/mL) for 3 days, respectively. Then, the supernatants were collected, and the levels of IL-6 and CXCL13 were assessed by ELISA. Autologous CD4 + T cells and CD19 + B cells were sorted from SMCs of patients with chronic HBV infection by FACS and cryopreserved in liquid nitrogen. Puri ed autologous CD4 + T cells were thawed and plated in a 96-well plate that was preseeded with FDCs at an 80:1 ratio (CD4 + T cells/FDCs), or with medium only as a control, and co-cultured in the presence of IL-2 (10 ng/mL) and anti-CD3/CD28 (10 μg/mL) for 3 days, the supernatants were collected, and the levels of IL-21 and IFN-γ were assessed by ELISA.
6
Temporal Gene Expression Profiling of HCV Patients
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This gene expression dataset was previously published and analyzed [32 (link)]. In brief, a total of 25 patients participated in this study, of which 6 patients were hepatitis C virus (HCV) negative and thus liver tissue expression data of these samples served as naive controls. The 19 HCV positive patients were receiving ribavirin and pegylated IFN-I treatment according to HCV genotype body weight and standard treatment recommendation. These patients agreed to be biopsied after receiving the first treatment dose of pegylated IFN-I (1.5 μg/kg body weight of pegIFN-α-2b (Essex Chemie) or 180 μg of pegIFN-α-2a (Roche)), at 4 hours (5 patients), 16 hours (3 patients), 48 hours (3 patients), 96 hours (3 patients) and 144 hours (5 patients).
7
Cytokine Expression and Cell Line Acquisition
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Human IFN-α2a was purchased from PeproTech (Rocky Hill, NJ, USA; Cat. #: 300-02A) and PEG-IFN-α2a (PEGASYS) from Hoffman-La Roche Ltd. (Basel, Switzerland). Wild-type IFN-λ1 and IFN-λ analogs were expressed and prepared in-house. The prokaryotic expression vector pET11a, together with the competent cell BL21 (DE3), was purchased from EMD Millipore (Billerica, MA, USA). HepG2, HEK293, and A549 cell lines were purchased from ATCC (Manassas, VA, USA). Huh-7.5.1 cells were kindly provided by F Chisari (Scripps Research Institute, La Jolla, CA, USA). Sources of other materials and reagents are described in the relevant sections. No ethics statement was required from the Institutional Review Board of Jilin University for the use of these cell lines.
8
Optimized Hepatitis C Treatment Based on Body Weight
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
According to disease status and body weight, enrolled patients were divided into two groups: routine-dose group (n = 40, body weight ≥ 60 kg, aged 18–60 years, treated with PegIFNα-2a at 180 μg/week); and low-dose group (n = 26, patients with compensated cirrhosis, leukocytopenia, body weight < 60 kg, aged 60–65 years, treated with PegIFNα-2a at 67.5–135 μg/week). As the mean body weights are lower for Chinese than Western patients, the dose of RBV was adjusted as follows: 900 mg/day for patients with body weight < 65 kg, 1000 mg/day if the body weight is 65–85 kg, and 1200 mg/day for those with body weight > 85 kg. In patients with undetectable HCV RNA, the treatment was given for an additional 44 weeks. Standard definitions of virological responses were used to assess the therapeutic effect. RVR was defined as undetectable serum HCV RNA at week 4 of therapy. SVR was defined as undetectable serum HCV RNA levels at 24 weeks post-therapy. PegIFNα-2a was obtained from F. Hoffmann-La Roche Ltd., Basel, Switzerland; and RBV was obtained from Zhejiang Chengyi Pharmaceutical Co., Ltd., Zhejiang, China.
9
HEV Infectious Virus Stock Generation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The infectious cDNA clones of HEV G1 (pSK-HEV-2 from the Sar-55 strain) (15 (link)) and G3 (p6 from the Kernow-C1 strain) were generous gifts from Dr. Suzanne U. Emerson (NIH, Bethesda, MD), whereas the infectious cDNA clone of G4 (pHEV-4TW from the TW6196E strain) has been described previously (37 (link)). The Huh7-S10-3 cell line was also a gift from Dr. Emerson. S10-3 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) containing 10% FBS (Gibco), penicillin (250 IU/mL) and streptomycin (250 μg/mL) at 37°C in the presence of 5% CO2. MRT67307, BX795, and ribavirin were purchased from Selleck Chemicals, and peg-IFNα-2a was purchased from Shanghai Roche Pharmaceuticals.
The G3 Kernow-C1 HEV infectious virus stock used for gerbil inoculation was rescued from the p6 infectious cDNA clones in S10-3 cells as described previously (16 (link), 36 (link)). The viral RNA titer of the rescued infectious HEV stock was determined by real-time qRT-PCR (56 (link)), with 6.83 × 106 genome equivalents (GE) of viral RNA/100 μL medium, giving an infectivity of 1 fluorescent focus-forming unit (FFU)/5,618 GE, as determined previously (50 (link)).
The G3 Kernow-C1 HEV infectious virus stock used for gerbil inoculation was rescued from the p6 infectious cDNA clones in S10-3 cells as described previously (16 (link), 36 (link)). The viral RNA titer of the rescued infectious HEV stock was determined by real-time qRT-PCR (56 (link)), with 6.83 × 106 genome equivalents (GE) of viral RNA/100 μL medium, giving an infectivity of 1 fluorescent focus-forming unit (FFU)/5,618 GE, as determined previously (50 (link)).
10
HEV Infectious Virus Stock Generation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The infectious cDNA clones of HEV G1 (pSK-HEV-2 from the Sar-55 strain) (15 (link)) and G3 (p6 from the Kernow-C1 strain) were generous gifts from Dr. Suzanne U. Emerson (NIH, Bethesda, MD), whereas the infectious cDNA clone of G4 (pHEV-4TW from the TW6196E strain) has been described previously (37 (link)). The Huh7-S10-3 cell line was also a gift from Dr. Emerson. S10-3 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) containing 10% FBS (Gibco), penicillin (250 IU/mL) and streptomycin (250 μg/mL) at 37°C in the presence of 5% CO2. MRT67307, BX795, and ribavirin were purchased from Selleck Chemicals, and peg-IFNα-2a was purchased from Shanghai Roche Pharmaceuticals.
The G3 Kernow-C1 HEV infectious virus stock used for gerbil inoculation was rescued from the p6 infectious cDNA clones in S10-3 cells as described previously (16 (link), 36 (link)). The viral RNA titer of the rescued infectious HEV stock was determined by real-time qRT-PCR (56 (link)), with 6.83 × 106 genome equivalents (GE) of viral RNA/100 μL medium, giving an infectivity of 1 fluorescent focus-forming unit (FFU)/5,618 GE, as determined previously (50 (link)).
The G3 Kernow-C1 HEV infectious virus stock used for gerbil inoculation was rescued from the p6 infectious cDNA clones in S10-3 cells as described previously (16 (link), 36 (link)). The viral RNA titer of the rescued infectious HEV stock was determined by real-time qRT-PCR (56 (link)), with 6.83 × 106 genome equivalents (GE) of viral RNA/100 μL medium, giving an infectivity of 1 fluorescent focus-forming unit (FFU)/5,618 GE, as determined previously (50 (link)).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!